A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients

A Double-blind, Randomised, Placebo-controlled, Parallel Group Multi-centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Bood and Uine of AZD1236 Administered as Oral Tablet in Moderate to Severe COPD Patients During a 6 Week Period.

The primary aim of this study is to investigate the effects of AZD1236 compared with placebo ("inactive substance") in COPD patients by analysing biomarkers for inflammation and tissue degradation in blood, urine and sputum.

Inclusion Criteria:

• Diagnosis of COPD for 1 month
• Men or postmenopausal women
• Spirometry values indicating symptomatic patients
• Smoking history equivalent to using 20 cigarettes a day for 10 years.

Exclusion Criteria:

• Any current respiratory tract disorders other than COPD
• Requirement for regular oxygen therapy
• Acute worsening of COPD (exacerbation) 1,5 month prior to study drug administration
• Use of oral or parenteral glucocorticosteroids within 30 days and use of inhaled steroids 14 days prior to the study